CV Sciences launches another product for new non-CBD immune health product line

Following the launch of its CV Acute product in August, CV Sciences (San Diego, CA) has announced the launch of its next condition-specific dietary supplement product called CV Defense. This is the second product in CV Science’s non-CBD Immunity product line that the firm believes will open markets and sales channels for the company that are not currently accessible to CBD-based products.

“The fall and winter of 2020/2021 is shaping up to be one of the most challenging times that we have experienced in global public health. Now is the time to commit to fortifying the immune system with healthy lifestyle habits and science-backed supplementation provided by CV Sciences new immune products – CV Defense and CV Acute,” said Michael D. Lewis, MD, MPH, Colonel (Retired), U.S. Army, and CV Sciences medical advisor, in a press release.

CV Defense is designed to support barrier immunity, innate immunity, and adaptive immunity with its formula comprised of PEA (palmitoylethanolamide), vitamins A and D, the minerals selenium and zinc, and an Organic Reishi Mushroom Extract with concentrated β-glucans. PEA has been clinically demonstrated to regulate immune cells in parallel with the endocannabinoid system.

“Our launch of CV Defense represents another key milestone in our strategic category expansion and continued evolution of CV Sciences’ positioning as a leading health and wellness company,” said Joseph Dowling, chief executive officer of CV Sciences, in a press release. “We are pleased to make CV Defense broadly available and accessible to consumers through our website and Amazon.com, further supporting our ability to bring immunity health products to market. In addition, we believe that our CBD product line will be ideal companion products to our Immunity line since CBD supports the endocannabinoid system (ECS), and a healthy ECS supports immune health.”